Tower Research Capital (TRC)’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Tower Research Capital (TRC)’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-840	Closed	-$8K	–	6732
2022 Q3	$8K	Sell	840 -10	-1%	-$99	﹤0.01%	4849
2022 Q2	$8K	Sell	850 -146	-15%	-$1.43K	﹤0.01%	4740
2022 Q1	$10K	Buy	996 +801	+411%	+$7.89K	﹤0.01%	4405
2021 Q4	$2K	Buy	+195	New	+$1.91K	﹤0.01%	5734
2021 Q3	–	Sell	-12	Closed	–	–	6408
2021 Q2	$0	Hold	12	–	–	﹤0.01%	6063
2021 Q1	$0	Buy	+12	New	+$116	﹤0.01%	5884

Other funds holding BIOT

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCP

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

RiverPark Advisors New York $219M AUM 14.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Tower Research Capital (TRC)'s BIOT Position: Q4 2022 in Review

Tower Research Capital (TRC) sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q4 2022, closing a stake of 840 shares — an estimated $8K sold.

Tower Research Capital (TRC) first reported a position in BIOT in Q1 2021 and held it in 6 quarters. The position peaked at $10K in Q1 2022. 68 funds tracked by Wall St. Rank hold BIOT as of Q4 2022.

Tower Research Capital (TRC) reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Tower Research Capital (TRC) sold 840 Biotech Acquisition Company Class A Ordinary Shares shares in Q4 2022, an estimated $8K.
Tower Research Capital (TRC) first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 6 quarters.
Tower Research Capital (TRC)'s Biotech Acquisition Company Class A Ordinary Shares position peaked at $10K in Q1 2022.
68 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q4 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.